Ewha Womans University has reported Bruton tyrosine kinase (BTK) inhibitors described as potentially useful for the treatment of autoimmune disease and cancer.

Kymera Therapeutics Inc. has reported signal transducer and activator of transcription 6 (STAT6) inhibitors.

Yuhan Corp. has disclosed triggering receptor expressed on myeloid cells 2 (TREM2) agonists described as potentially useful for the treatment of neurological disorders.

Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of arthritis and psoriasis.

Voronoi Inc. has divulged hepatocyte growth factor receptor (HGFR; c-MET) inhibitors. They are reported to be useful for the treatment of cancer.

Sundance Biosciences Inc. has discovered non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of multiple sclerosis.

Scientists from Merck Sharp & Dohme LLC and Otsuka Pharmaceutical Co. Ltd. have identified cellular tumor antigen p53 (TP53) Y220C mutant stabilizers reported to be useful for the treatment of cancer.

Aquinnah Pharmaceuticals Inc. has disclosed new microtubule-associated protein τ (PHF-τ; MAPT) aggregation inhibitors designed for use in the treatment of Alzheimer’s disease and frontotemporal dementia.

Kunshan Xinyunda Biotechnology Co. Ltd. has discovered antibody-drug conjugates (ADCs) consisting of antibodies covalently linked to cytotoxic drugs potentially useful for the treatment of cancer.

Scientists from Shenzhen Medical Academy of Research and Translation and the Southern Medical University have synthesized solute carrier family 22 member 12 (SLC22A12; URAT1) inhibitors. They are reported to be useful for the treatment of kidney injury, hyperuricemia and gout.